RyR2 inhibition with dantrolene is antiarrhythmic, antifibrotic, and improves cardiac function in chronic ischemic heart disease
J. D. Schmeckpeper, K. Kim, S. A. George, D. J. Blackwell, J. A. Brennan, I. R. Efimov, B. C. Knollmann
This study shows that dantrolene reduces ventricular tachycardia, fibrosis, and improves cardiac function in a mouse model of chronic ischemic heart disease.
bioRxiv · Jun 24, 2022 · PreprintPharmacology & Toxicology